Evidence map›Paper›PMID 42552079›Full record

ArticleGenes & development2026

An antisense antidote to oncogenic poison exons.

René M Arvola, Guramrit Singh

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

René M ArvolaDepartment of Molecular Genetics, Center for RNA Biology, The Ohio State University, Columbus, Ohio 43210, USA.
Guramrit SinghDepartment of Molecular Genetics, Center for RNA Biology, The Ohio State University, Columbus, Ohio 43210, USA singh.734@osu.edu.

Funding

Post-transcriptional gene regulation by the exon junction complexR35GM149298 · NIGMS · OHIO STATE UNIVERSITY · PI Guramrit Singh · 2023 to 2026
$1.6M
Investigating UPF3 paralog function in Nonsense-Mediated mRNA Decay and Genetic CompensationK99GM154061 · NIGMS · OHIO STATE UNIVERSITY · PI ARVOLA, RENE MARLENE · 2024 to 2025
$330k
NIGMS NIH HHS K99 GM154061NIGMS NIH HHS R35 GM149298
6 · The paper itself

Abstract

Splicing factors are frequently mutated in myeloid cancers, causing splicing aberrations that derail the expression of tumor suppressor genes. In SRSF2 mutated cancers, a key oncogenic splicing event is the inclusion of a "poison" exon that introduces an early stop codon in

Indexed as

ExonsOligonucleotides, AntisenseAnimalsEnhancer of Zeste Homolog 2 ProteinHumansRNA SplicingSerine-Arginine Splicing FactorsEnhancer of Zeste Homolog 2 ProteinOligonucleotides, AntisenseSerine-Arginine Splicing Factorsantisense oligonucleotide therapycancergene expressionnonsense-mediated mRNA decayRNA splicing

Identifiers

PMID42552079
PMCPMC13532538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.